Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Devoogdt

Showing results (1-10 of 153) with videos related to

Pageof 16
Sort By:
Antibodies (Basel, Switzerland)|September 24, 2019
Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided SurgeryPieterjan Debie, Nick Devoogdt, Sophie Hernot
Expert Opinion on Drug Delivery|April 28, 2016
Emerging site-specific bioconjugation strategies for radioimmunotracer developmentSam Massa, Catarina Xavier, Serge Muyldermans, et al.
International Journal of Molecular Sciences|December 30, 2020
The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a CharmQuentin Lecocq, Marleen Keyaerts, Nick Devoogdt, et al.
Pharmaceutics|August 4, 2019
Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and MetastasesJanik Puttemans, Tony Lahoutte, Matthias D'Huyvetter, et al.
Expert Opinion on Biological Therapy|May 17, 2013
Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its targetJens De Vos, Nick Devoogdt, Tony Lahoutte, et al.
Bioconjugate Chemistry|November 3, 2018
An Efficient Method for Labeling Single Domain Antibody Fragments with <sup>18</sup>F Using Tetrazine- Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable LinkerZhengyuan Zhou, Nick Devoogdt, Michael R Zalutsky, et al.
Annals of the New York Academy of Sciences|January 15, 2005
Secretory leukocyte protease inhibitor in cancer developmentNick Devoogdt, Hilde Revets, Gholamreza Hassanzadeh Ghassabeh, et al.
Cancers|January 23, 2024
Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer ManagementYing Cong, Nick Devoogdt, Philippe Lambin, et al.
Molecular Pharmaceutics|November 15, 2018
Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[<sup>18</sup>F]Fluoronicotinate Resulting in High Tumor-to-Kidney RatiosZhengyuan Zhou, Darryl McDougald, Nick Devoogdt, et al.
Medicinal Research Reviews|May 24, 2021
The antigen-binding moiety in the driver's seat of CARsHeleen Hanssens, Fien Meeus, Kim De Veirman, et al.
Pageof 16

Showing results (1-10 of 153) with videos related to

Sort By:
Pageof 16
Antibodies (Basel, Switzerland)|September 24, 2019
Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided SurgeryPieterjan Debie, Nick Devoogdt, Sophie Hernot
Expert Opinion on Drug Delivery|April 28, 2016
Emerging site-specific bioconjugation strategies for radioimmunotracer developmentSam Massa, Catarina Xavier, Serge Muyldermans, et al.
International Journal of Molecular Sciences|December 30, 2020
The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a CharmQuentin Lecocq, Marleen Keyaerts, Nick Devoogdt, et al.
Pharmaceutics|August 4, 2019
Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and MetastasesJanik Puttemans, Tony Lahoutte, Matthias D'Huyvetter, et al.
Expert Opinion on Biological Therapy|May 17, 2013
Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its targetJens De Vos, Nick Devoogdt, Tony Lahoutte, et al.
Bioconjugate Chemistry|November 3, 2018
An Efficient Method for Labeling Single Domain Antibody Fragments with <sup>18</sup>F Using Tetrazine- Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable LinkerZhengyuan Zhou, Nick Devoogdt, Michael R Zalutsky, et al.
Annals of the New York Academy of Sciences|January 15, 2005
Secretory leukocyte protease inhibitor in cancer developmentNick Devoogdt, Hilde Revets, Gholamreza Hassanzadeh Ghassabeh, et al.
Cancers|January 23, 2024
Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer ManagementYing Cong, Nick Devoogdt, Philippe Lambin, et al.
Molecular Pharmaceutics|November 15, 2018
Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[<sup>18</sup>F]Fluoronicotinate Resulting in High Tumor-to-Kidney RatiosZhengyuan Zhou, Darryl McDougald, Nick Devoogdt, et al.
Medicinal Research Reviews|May 24, 2021
The antigen-binding moiety in the driver's seat of CARsHeleen Hanssens, Fien Meeus, Kim De Veirman, et al.
Pageof 16